IBI110

DRUG5 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Fudan University

Conditions

Advanced MalignanciesDLBCLHead and Neck CancerHead and Neck Squamous Cell CarcinomaNon-small Cell Lung Cancer (NSCLC)SCLC

Phase 1

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Innovent Biologics (Suzhou) Co. Ltd.Advanced Malignancies

Start: 2019-12-04End: 2024-06-30Target: 268Updated: 2022-09-14

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

CompletedNCT05026593

Innovent Biologics (Suzhou) Co. Ltd.SCLC

Start: 2021-09-07End: 2023-06-26Updated: 2023-07-19

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Innovent Biologics (Suzhou) Co. Ltd.DLBCL

Start: 2021-09-27End: 2022-12-02Target: 50Updated: 2021-09-09

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

TerminatedNCT05088967

Innovent Biologics (Suzhou) Co. Ltd.Non-small Cell Lung Cancer (NSCLC)

Start: 2021-12-02End: 2023-12-25Updated: 2024-01-16

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

RecruitingNCT06494943

Fudan UniversityHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma

Start: 2024-06-26End: 2028-12-31Target: 27Updated: 2025-02-25

Related Papers

Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.

2026-01-27

Neoadjuvant IBI110 and sintilimab in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma.

Journal of Clinical Oncology2025-05-28

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study.

2024-12-3110 citations

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.

Journal of Clinical Oncology2023-06-012 citations

Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.

Journal of Clinical Oncology2023-06-011 citations

IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study.

Journal of Clinical Oncology2022-06-018 citations

Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study.

Journal of Clinical Oncology2022-06-012 citations

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study.

Journal of Clinical Oncology2022-06-011 citations

Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2021-05-201 citations